Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Effectiveness of a Mother-Centered Infection Prevention (MCIP) Educational Intervention in Reducing Infections Among Pediatric Oncology Patients: A Randomized Controlled Trial

ALL - 025

Effectiveness of a Mother-Centered Infection Prevention (MCIP) Educational Intervention in Reducing Infections Among Pediatric Oncology Patients: A Randomized Controlled Trial

Ana Farooq

Poster Presenter: Ana Farooq

Thumbnail for Effects of Ianalumab Treatment on B-Cell Activation, Maturation, and Maintenance of Vaccine Titers in Patients With Primary Immune Thrombocytopenia (ITP) in the Phase 2 VAYHIT3 Study

MDS - 600

Effects of Ianalumab Treatment on B-Cell Activation, Maturation, and Maintenance of Vaccine Titers in Patients With Primary Immune Thrombocytopenia (ITP) in the Phase 2 VAYHIT3 Study

Jenny Despotovic

Poster Presenter: Jenny Despotovic

Previous 1...40 41 42 43 44 45 46...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

$Thumbnail for Efficacy and Differentiation Syndrome With Menin Inhibitors in Relapsed/Refractory KMT2A-Rearranged or NPM1-Mutated Acute Leukemia: An Exploratory Proportional Meta-Analysis$

AML - 848

Efficacy and Differentiation Syndrome With Menin Inhibitors in Relapsed/Refractory KMT2A-Rearranged or NPM1-Mutated Acute Leukemia: An Exploratory Proportional Meta-Analysis

Farzeen Fatma Syed

Poster Presenter: Farzeen Fatma Syed

Thumbnail for Efficacy and Molecular Dynamics of Ropeginterferon Alfa-2b in High-Risk Essential Thrombocythemia: 2-Year Results from the Phase 3 SURPASS-ET Trial

MPN - 944

Efficacy and Molecular Dynamics of Ropeginterferon Alfa-2b in High-Risk Essential Thrombocythemia: 2-Year Results from the Phase 3 SURPASS-ET Trial

Lucia Masarova

Poster Presenter: Lucia Masarova

Thumbnail for Efficacy and Safety of a Pakistan-Manufactured Generic Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A Multicenter Phase 4 Study

CML - 1023

Efficacy and Safety of a Pakistan-Manufactured Generic Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A Multicenter Phase 4 Study

Zeba Aziz

Poster Presenter: Zeba Aziz

Thumbnail for Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Adults With Immune Thrombocytopenia: A Systematic Review and Single-Arm Meta-Analysis

CT - 587

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Adults With Immune Thrombocytopenia: A Systematic Review and Single-Arm Meta-Analysis

Gamaliel Monge-Ruiz

Poster Presenter: Gamaliel Monge-Ruiz

Thumbnail for Efficacy and Safety of Anti-CD38 Monoclonal Antibody-Based Regimens in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

MM - 980

Efficacy and Safety of Anti-CD38 Monoclonal Antibody-Based Regimens in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

FNU Raja

Poster Presenter: Fnu Raja

Thumbnail for Efficacy and Safety of Asciminib as Second-Line or Later Therapy in Chronic-Phase Chronic Myeloid Leukemia: An Updated Systematic Review and Meta-Analysis

CML - 426

Efficacy and Safety of Asciminib as Second-Line or Later Therapy in Chronic-Phase Chronic Myeloid Leukemia: An Updated Systematic Review and Meta-Analysis

Shivam Rainchwar

Poster Presenter: Shivam Rainchwar

Thumbnail for Efficacy and Safety of Asciminib Dose Escalation in Patients with Chronic Myeloid Leukemia (CML) without Optimal Response to the Standard Dose

CML - 1134

Efficacy and Safety of Asciminib Dose Escalation in Patients with Chronic Myeloid Leukemia (CML) without Optimal Response to the Standard Dose

Elza Lomaia

Poster Presenter: Elza Lomaia

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors